Leerink Partners Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price

Posted by Geri Gentry on Nov 5th, 2026

Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) had its price objective raised by Leerink Partners from $50.00 to $54.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Leerink Partners‘s target price would suggest a potential upside of 87.25% from the stock’s previous close.

A number of other brokerages have also weighed in on VRDN. HC Wainwright raised their target price on shares of Viridian Therapeutics from $22.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday. Needham & Company LLC upped their price target on shares of Viridian Therapeutics from $34.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday. Wells Fargo & Company increased their price target on Viridian Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a research note on Thursday. Weiss Ratings raised Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 14th. Finally, Royal Bank Of Canada raised their price objective on Viridian Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Tuesday, September 22nd. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Viridian Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $41.00.

Check Out Our Latest Analysis on VRDN

Viridian Therapeutics Price Performance

Shares of VRDN traded down $0.22 during mid-day trading on Thursday, reaching $28.84. The company had a trading volume of 2,414,244 shares, compared to its average volume of 2,154,895. The company has a market capitalization of $3.27 billion, a price-to-earnings ratio of -8.55 and a beta of 1.07. The company has a debt-to-equity ratio of 0.43, a quick ratio of 16.95 and a current ratio of 16.95. The company’s 50 day simple moving average is $21.80 and its 200 day simple moving average is $21.85. Viridian Therapeutics has a 1-year low of $13.18 and a 1-year high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.21. The business had revenue of $25.75 million during the quarter, compared to analysts’ expectations of $4.72 million. Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 72.97%. Analysts expect that Viridian Therapeutics will post -4.07 EPS for the current year.

Insider Buying and Selling at Viridian Therapeutics

In related news, insider Jennifer Tousignant sold 14,212 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total value of $348,194.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 2.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Wellington Management Group LLP lifted its holdings in Viridian Therapeutics by 1.6% during the 2nd quarter. Wellington Management Group LLP now owns 3,128,362 shares of the company’s stock worth $57,468,000 after buying an additional 49,808 shares during the period. Parkman Healthcare Partners LLC acquired a new stake in shares of Viridian Therapeutics in the second quarter valued at about $25,306,000. Rice Hall James & Associates LLC acquired a new stake in shares of Viridian Therapeutics in the second quarter valued at about $21,601,000. Bank of America Corp DE increased its stake in shares of Viridian Therapeutics by 17.5% in the first quarter. Bank of America Corp DE now owns 1,163,615 shares of the company’s stock valued at $22,760,000 after buying an additional 173,498 shares during the period. Finally, Elmind Capital LP bought a new position in shares of Viridian Therapeutics during the second quarter worth about $18,093,182.

Key Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

Positive Sentiment: Four firms raised their targets and maintained bullish ratings: Truist lifted its target to $42, Wells Fargo to $34, Wedbush to $42, and HC Wainwright to $40. Needham also raised its target to $38. These upgrades point to continued analyst optimism. Truist rating Wells Fargo rating Wedbush rating HC Wainwright rating Needham rating
Positive Sentiment: Viridian reported a third-quarter loss of $0.81 per share, narrower than analysts’ roughly $1.01–$1.02 estimate, and revenue of $25.75 million versus a $4.72 million consensus. The earnings and revenue beats may support confidence in its progress. Q3 results
Positive Sentiment: Viridian is targeting broad coverage for its Lumvoa launch in six to nine months and expects to submit an elegrobart biologics license application in the first quarter of 2027. These commercial and regulatory milestones could provide near-term catalysts, though execution remains important. Lumvoa and elegrobart update
Negative Sentiment: Despite beating estimates, the quarterly loss widened from $0.34 per share a year earlier to $0.81, underscoring that Viridian remains loss-making. A separate commentary also argued the stock may be overvalued even with its new launch, raising valuation concerns after recent optimism. Valuation commentary

Viridian Therapeutics Company Profile

(Get Free Report)

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.